Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

89 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03462342 2026-04-13

CAPRI

Phase 2 Completed

123 enrolled

High Grade Serous Carcinoma

NCT04704661 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1 Recruiting

51 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06732401 2026-04-13

CLEAR

Phase 3 Active not recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03878095 2026-04-08

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2 Active not recruiting

24 enrolled 12 charts

Gastrointestinal

Cholangiocarcinoma

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

900 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Phase 1 Active not recruiting

14 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

39 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2 Active not recruiting

63 enrolled

Sarcoma

Osteosarcoma

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

96 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06929260 2026-01-22

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

Phase 1 Terminated

1 enrolled

Other solid neoplasm

Advanced Solid Tumours

Clinical Trials

LATIFY

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

CAPRI

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

CLEAR

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

LOTOS

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z